Tuesday, March 19, 2019 Daily Archives

Thermo Fisher injecting $150m in Patheon fill & finish plants

by

Two facilities in Italy and a site in Greenville, North Carolina are being expanded to support demand for biologics aseptic liquid and lyophilized product development and manufacturing. Since Thermo Fisher acquired contract development and manufacturing organization (CDMO) Patheon for $7.2 billion (€6.4 billion) in August 2017, the firm has invested $50 million to double single-use capacity at the St Louis, Missouri biologics facility. Now Thermo Fisher is investing further in the Patheon network through expansions at three global fill & finish…

March 19, 2019

Lonza’s POC CAR-T tech: Out with the cleanroom, in with the Cocoon

by

Lonza will provide its point-of-care (POC) Cocoon cell therapy platform to the Sheba Medical Center in Israel to provide automated and closed CAR-T manufacturing. The collaboration between Sheba and Swiss contract development and manufacturing organization (CDMO) Lonza aims to confirm the benefits of using the Cocoon system to make autologous cell therapies in a POC environment. “The partnership with Sheba will test the Cocoon in the clinical setting,†Eytan Abraham, head of Personalized Medicine at Lonza Pharma Biotech, told Bioprocess…

March 19, 2019

New clients and Halozyme drive robust Q3 for Avid

by

Avid Bioservices has attributed its strong third quarter to the diversification of its customer base and the return of demand from its largest customer Halozyme. When Avid Bioservice became a pure contract development and manufacturing organization (CDMO) in early 2018, it stated the expansion and diversification of its customer base as one of its near-term strategic objectives. A year on and Avid has reported a robust third quarter fiscal year 2019 driven by an increase in the number of manufacturing…

March 19, 2019